News

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...
Throughout the last three months, 11 analysts have evaluated BioNTech (NASDAQ:BNTX), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings ...
An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations ...
Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), its partner for the Comirnaty COVID-19 vaccine, made legal submissions to London's Court of Appeal on Thursday seeking to overturn a prior court ruling ...
CureVac N.V. (NASDAQ:CVAC) is among the 13 Best German Stocks to Invest in Now. The stock has gained by over 16% in the past month, with a major surge following the June 12 announcement that the ...
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The ...
The race to develop effective cancer vaccines has entered a new phase, with late-stage trials from companies like Moderna ...
BioNTech (NASDAQ:BNTX – Get Free Report) had its price target lowered by investment analysts at HC Wainwright from $145.00 to $138.00 in a research note issued to investors on Monday,Benzinga ...
Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the ...
Ryan Richardson joined BioNTech in 2018 and has served as Chief Strategy Officer since January 2020. During his time at the Company, he contributed significantly to BioNTech’s successful development, ...
Robeco Institutional Asset Management B.V. cut its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report) by 23.5% in the first quarter, according to the company in its most ...
In Germany, a court in the city of Düsseldorf ruled in March that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) violated a COVID-19 vaccine patent asserted by Moderna (MRNA).